Methods and compositions to modulate t cell metabolism, function, and fate
AssigneeCornell University
InventorsJuan R. Cubillos-Ruiz, Sung-Min Hwang
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to compositions and methods for treating cancers (e.g., ovarian cancer) or increasing cytotoxicity of T cells by modulating expression, level, and/or activity of Transgelin-2 (TAGLN2) in T cells. It also discloses vectors to increase expression, level, and/or activity of TAGLN2 in T cells, T cells co-expressing a CAR and TAGLN2, and adaptive cell therapies using such T cells. Methods of assessing functional status and/or anti-tumor activity of T cells using TAGLN2 as a biomarker are also disclosed.
Claims34
A method of treating a subject afflicted with a cancer, comprising administering to the subject an agent that increases expression, level, and/or activity of Transgelin-2 (TAGLN2) in T cells.
-6. (canceled)
(canceled)
-11. (canceled)
A method of increasing cytotoxicity of a T cell comprising contacting the T cell with an agent that increases expression, level, and/or activity of Transgelin-2 (TAGLN2) in the T cell.
-17. (canceled)
(canceled)
-24. (canceled)
-32. (canceled)
-55. (canceled)
A T cell expressing a chimeric antigen receptor (CAR) and comprising a transgene encoding TAGLN2.
-60. (canceled)
(canceled)
(canceled)
(canceled)
(canceled)
-100. (canceled)
Dependencies are inferred from the claim text.